Catenin Beta 1 (Beta Catenin or CTNNB1) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Catenin Beta 1 (Beta Catenin or CTNNB1) – Pipeline Review, H2 2017’, provides in depth analysis on Catenin Beta 1 (Beta Catenin or CTNNB1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Dermatology, Gastrointestinal, Genetic Disorders and Other Diseases under development targeting Catenin Beta 1 (Beta Catenin or CTNNB1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)

The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects

The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Boston Biomedical Inc

Dicerna Pharmaceuticals Inc

Marina Biotech Inc

Propanac Biopharma Inc

Warp Drive Bio Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview 7

Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development 21

Boston Biomedical Inc 21

Dicerna Pharmaceuticals Inc 21

Marina Biotech Inc 21

Propanac Biopharma Inc 22

Warp Drive Bio Inc 22

Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles 23

Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

BBI-801 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

exisulind - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

M-101 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

M-102 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

M-201 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

nefopam hydrochloride - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Oligonucleotides for Hepatoblastoma - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

PRP - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecules to Inhibit Beta-Catenin for Oncology - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

WX-024 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products 43

Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones 45

Featured News & Press Releases 45

Sep 27, 2017: Propanc Biopharma Highlights Therapeutic Potential of PRP 45

Aug 30, 2017: Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies 45

Aug 02, 2017: Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study 46

Jul 27, 2017: Propanc Biopharma Provides Shareholder Update on R&D Activities for PRP 47

Jul 20, 2017: Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China 48

Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017 48

Jun 26, 2017: Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer 49

Jun 09, 2017: Propanc Biopharma Makes Significant Progress with PCT Patent Application 50

May 19, 2017: Propanc Biopharma Highlights PRP's Potential to Reprogram Cancer Stem Cells 50

May 16, 2017: Propanc Biopharma Awaits FDA Response to Orphan Drug Designation Request for Treatment of Pancreatic Cancer, as PRP Progresses to First-In-Human Studies 51

May 02, 2017: Propanc Biopharma Provides Update on Investigational Medicinal Product Manufacture of PRP for First-In-Human Studies 52

Apr 27, 2017: Propanc Successfully Completes 28-Day Repeat-Dose Toxicity Study for PRP 53

Apr 04, 2017: Boston Biomedical Presents New Preclinical Data on BBI-801 at AACR 2017 Highlighting the Potential Role of Cancer Stemness Inhibition 53

Feb 14, 2017: Propanc Successfully Completes Low Dose Group for GLP-Compliant 28-Day Repeat-Dose Toxicity Study 54

Jan 24, 2017: Propanc Provides Progress Update on Additional Patent Applications 55

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Number of Products under Investigation by Universities/Institutes, H2 2017 13

Products under Investigation by Universities/Institutes, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 18

Number of Products by Stage and Molecule Type, H2 2017 20

Pipeline by Boston Biomedical Inc, H2 2017 21

Pipeline by Dicerna Pharmaceuticals Inc, H2 2017 21

Pipeline by Marina Biotech Inc, H2 2017 22

Pipeline by Propanac Biopharma Inc, H2 2017 22

Pipeline by Warp Drive Bio Inc, H2 2017 22

Dormant Products, H2 2017 43

Dormant Products, H2 2017 (Contd..1), H2 2017 44

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Routes of Administration, H2 2017 17

Number of Products by Stage and Routes of Administration, H2 2017 17

Number of Products by Molecule Types, H2 2017 19

Number of Products by Stage and Molecule Types, H2 2017 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports